|Event:||2016 NEI Psychopharmacology Congress|
|Title:||The Efficacy and Safety of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine, for the Treatment of Military-Related PTSD|
|Date:||Friday, November 4, 2016|
|Location:||Exhibit Hall, Poster No. 186, The Broadmoor, Colorado Springs, CO|
NEW YORK, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present efficacy and safety results of TNX-102 SL* for the treatment of military-related PTSD in a poster at the 2016 NEI Psychopharmacology Congress being held November 3-6, 2016 in Colorado Springs, CO. Gregory Sullivan, M.D., chief medical officer of Tonix, will present the poster, titled, "The Efficacy and Safety of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine, for the Treatment of Military-Related PTSD" (Poster No.: 186). Tonix recently held a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) based on positive data from its 12-week randomized, double-blind, placebo-controlled Phase 2 AtEase clinical trial. Tonix intends to commence a 12-week Phase 3 study evaluating TNX-102 SL, 5.6 mg, in military-related PTSD in the first quarter of 2017.
*TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an Investigational New Drug and has not been approved for any indication.